Cargando…

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients

Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharyya, Sudeepa, Ahmed, Ahmed T., Arnold, Matthias, Liu, Duan, Luo, Chunqiao, Zhu, Hongjie, Mahmoudiandehkordi, Siamak, Neavin, Drew, Louie, Gregory, Dunlop, Boadie W., Frye, Mark A., Wang, Liewei, Weinshilboum, Richard M., Krishnan, Ranga R., Rush, A. John, Kaddurah-Daouk, Rima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609722/ https://www.ncbi.nlm.nih.gov/pubmed/31273200 http://dx.doi.org/10.1038/s41398-019-0507-5

Ejemplares similares

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2021)

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety—A Role for Bile Acids
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2022)

Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
por: Brydges, Christopher R., et al.
Publicado: (2021)

Rise of escitalopram and the fall of citalopram
por: Cavanah, Luke R., et al.
Publicado: (2023)

ERICH3: vesicular association and antidepressant treatment response
por: Liu, Duan, et al.
Publicado: (2020)

Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication
por: Joyce, Jeremiah B., et al.
Publicado: (2021)

The Metabolome-Wide Signature of Major Depressive Disorder
por: Jansen, Rick, et al.
Publicado: (2023)

Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study
por: Qirjazi, Elena, et al.
Publicado: (2016)

Prediction of Ventricular Arrhythmias by QRS/QTc - Ratio in Citalopram or Escitalopram Intoxication
por: Dietrichs, Erik Sveberg, et al.
Publicado: (2022)

Assessment of citalopram and escitalopram on neuroblastoma cell lines: Cell toxicity and gene modulation
por: Sakka, Laurent, et al.
Publicado: (2017)

Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data
por: de Bardeci, Mateo, et al.
Publicado: (2022)

Metabolic Profiling of Patients with Schizophrenia
por: Kaddurah-Daouk, Rima
Publicado: (2006)

Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression
por: Nho, Kwangsik, et al.
Publicado: (2021)

Micelle Enhanced Fluorimetric and Thin Layer Chromatography Densitometric Methods for the Determination of (±) Citalopram and its S – Enantiomer Escitalopram
por: Taha, Elham A., et al.
Publicado: (2009)

Effect of Proton Pump Inhibitors on the Serum Concentrations of the Selective Serotonin Reuptake Inhibitors Citalopram, Escitalopram, and Sertraline
por: Gjestad, Caroline, et al.
Publicado: (2015)

Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication
por: Athreya, Arjun P., et al.
Publicado: (2019)

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics
por: Liu, Duan, et al.
Publicado: (2018)

Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants
por: Alkhafaji, Ali A, et al.
Publicado: (2012)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole Pathway
por: Zhu, Hongjie, et al.
Publicado: (2013)

Single Nucleotide Polymorphisms at a Distance from Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand–Dependent Gene Expression
por: Neavin, Drew R., et al.
Publicado: (2019)

Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders
por: Aldrich, Stacey L., et al.
Publicado: (2019)

Double blind, randomised trial to compare efficacy of escitalopram versus citalopram for interferon induced depression in hepatitis C patients
por: Shakeel, Uzma, et al.
Publicado: (2020)

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
por: Lalit, Vaya, et al.
Publicado: (2004)

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Qin, Sisi, et al.
Publicado: (2019)

Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer’s Disease
por: Baloni, Priyanka, et al.
Publicado: (2020)

The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases
por: Neavin, Drew R., et al.
Publicado: (2018)

Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population‐based cohort study in older adults
por: Aakjær, Mia, et al.
Publicado: (2022)

Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
por: Beger, Richard D., et al.
Publicado: (2020)

Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings
por: Athreya, Arjun P., et al.
Publicado: (2021)

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Pro-arrhythmic effect of escitalopram and citalopram at serum concentrations commonly observed in older patients – a study based on a cohort of 19,742 patients
por: Faraj, Pari, et al.
Publicado: (2023)

Escitalopram-induced extrapyramidal symptoms
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2019)

An interesting case of serotonin syndrome precipitated by escitalopram
por: Sanyal, Debasish, et al.
Publicado: (2010)

Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers
por: Nho, Kwangsik, et al.
Publicado: (2019)

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Baseline thyroid indices and the subsequent response to citalopram treatment, a pilot study
por: Abulseoud, Osama A, et al.
Publicado: (2013)

Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts
por: St. John-Williams, Lisa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ks89c30dvuqqf74md43i46sck1